Erica Mackenzie

Erica Mackenzie

Auto-generated profile, based on publicly available information

Erica Mackenzie

Department of Infectious Diseases, The University of Kansas Medical Center, Kansas City, Kansas

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2024 in American Journal of Hematology
Verified
Journal Article
Open access
JSJon Salmanton-García
Jon Salmanton-García
FMFrancesco Marchesi
Francesco Marchesi
MNMilan Navrátil
Milan Navrátil
KPKlára Piukovics
Klára Piukovics
MPMaria Ilaria del Principe
Maria Ilaria del Principe
Livio PaganoLivio Pagano
Livio Pagano
Community‐acquired respiratory viral infections (CARV) significantly impact patients with hematological malignancies (HM), leading to high morbidity and mortality. However, large‐scale, real‐world data on CARV in these patients is limited. This study analyzed data from the EPICOVIDEHA‐EPIFLUEHA registry, focusing on patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. The study assessed epidemiology, clinical characteristics, risk factors, and outcomes. The study examined 1312 patients with HM diagnosed with CARV during the 2023–2024 autumn–winter season. Of these, 59.5% required hospitalization, with 13.5% needing ICU admission. The overall mortality rate was 10.6%, varying by virus: parainfluenza (21.3%), influenza (8.8%), metapneumovirus (7.1%), RSV (5.9%), or SARS‐CoV‐2 (5.0%). Poor outcomes were significantly associated with smoking history, severe lymphopenia, secondary bacterial infections, and ICU admission. This study highlights the severe risk CARV poses to patients with HM, especially those undergoing active treatment. The high rates of hospitalization and mortality stress the need for better prevention, early diagnosis, and targeted therapies. Given the severe outcomes with certain viruses like parainfluenza, tailored strategies are crucial to improving patient outcomes in future CARV seasons.

24 December 2025 in American Journal of Hematology
Verified
Journal Article
Open access
JSJon Salmanton-García
Jon Salmanton-García
FMFrancesco Marchesi
Francesco Marchesi
MNMilan Navrátil
Milan Navrátil
IFIker Falces‐Romero
Iker Falces‐Romero
MPMaria Ilaria Del Principe
Maria Ilaria Del Principe
Livio PaganoLivio Pagano
Livio Pagano

27 February 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
JSJon Salmanton-García
Jon Salmanton-García
FMFrancesco Marchesi
Francesco Marchesi
EMErica Mackenzie
Erica Mackenzie
IHInmaculada Heras-Fernando
Inmaculada Heras-Fernando
IFIker Falces-Romero
Iker Falces-Romero
OCOliver A. Cornely
Oliver A. Cornely
Background: Human metapneumovirus (hMPV) is an increasingly recognized respiratory pathogen in immunocompromised patients, but its impact in haematological malignancies is poorly defined. Unlike influenza or SARS-CoV-2, hMPV has no specific treatment or vaccine, contributing to underdiagnosis and underestimation of its clinical relevance. Method: We performed a multicentre retrospective cohort study within the Epidemiology of COVID-19 in patients with hematological malignancies: A European Haematology Association Survey/ Epidemiology of respiratory viral infections in patients with hematological malignancies: A European Haematology Association Survey registry of haematological patients with hMPV (January 2023–December 2024), comparing clinical features and outcomes with matched influenza and SARS-CoV-2 cohorts. Results: The study included 130 patients with hMPV. Median age was 58.5 years; 57% were male. Plasma cell neoplasms (25%), lymphoma (23%), and acute myeloid leukemia (20%) were the most common hematological malignancies. Hospitalization occurred in 64%, intensive care unit (ICU) admission in 19%, and 30-day mortality was 8%. Most cases (73%) received supportive care only. Secondary infections were common (24%). Chronic renal disease significantly increased mortality risk (hazard ratio 20.9 11.05, P = .014). Compared with influenza and SARS-CoV-2, hMPV patients had comparable severity and outcomes, with 18.5% ICU admission rates versus 25.9% for influenza (P = .316) and 20.9% versus 4.7% for SARS-CoV-2 (P = .006), and 30-day mortality of 5.6% versus 11.1% for influenza (P = .489) and 7.0% versus 2.3% for SARS-CoV-2 (P = .277), yet received fewer targeted interventions. Conclusions: hMPV causes clinically significant disease in patients with hematological malignancy, often necessitating hospital and ICU care, and leading to mortality. In the absence of specific treatments or vaccines, this virus remains an underrecognized pathogen in patients with hematological malignancy. Enhanced clinical awareness and investment in diagnostics, prevention, and therapeutics are needed.